Hangzhou Jiuyuan Genetic Biopharmaceutical (02566) Reports Share Repurchase and Updated Shareholding Structure

Bulletin Express

Feb 04

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed a repurchase of 680,400 H shares on 4 February 2026. The company’s opening balance on 3 February 2026 showed 107,208,585 issued shares (excluding treasury shares) and 1,888,200 treasury shares, totaling 109,096,785 shares.

Following the repurchase, the number of issued shares (excluding treasury shares) decreased to 106,528,185, while treasury shares increased to 2,568,600. The total number of issued shares remained at 109,096,785. Repurchase prices ranged between HKD 9.81 and HKD 10.74, resulting in an aggregate consideration of approximately HKD 7.26 million.

According to the disclosure, there is a moratorium period extending to 6 March 2026, during which no new shares may be issued or released from treasury without prior approval. The update reflects the most recent changes in the company’s shareholding structure recorded as of 4 February 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137991191"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137991191\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137991191?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137991191","market":"hk","top_or_hot":-1,"title":"Hangzhou Jiuyuan Genetic Biopharmaceutical (02566) Reports Share Repurchase and Updated Shareholding Structure","media":"Bulletin Express","content":"<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed a repurchase of 680,400 H shares on 4 February 2026. The company’s opening balance on 3 February 2026 showed 107,208,585 issued shares (excluding treasury shares) and 1,888,200 treasury shares, totaling 109,096,785 shares.</p>\n<p>Following the repurchase, the number of issued shares (excluding treasury shares) decreased to 106,528,185, while treasury shares increased to 2,568,600. The total number of issued shares remained at 109,096,785. Repurchase prices ranged between HKD 9.81 and HKD 10.74, resulting in an aggregate consideration of approximately HKD 7.26 million.</p>\n<p>According to the disclosure, there is a moratorium period extending to 6 March 2026, during which no new shares may be issued or released from treasury without prior approval. The update reflects the most recent changes in the company’s shareholding structure recorded as of 4 February 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Jiuyuan Genetic Biopharmaceutical (02566) Reports Share Repurchase and Updated Shareholding Structure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Jiuyuan Genetic Biopharmaceutical (02566) Reports Share Repurchase and Updated Shareholding Structure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-04 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed a repurchase of 680,400 H shares on 4 February 2026. The company’s opening balance on 3 February 2026 showed 107,208,585 issued shares (excluding treasury shares) and 1,888,200 treasury shares, totaling 109,096,785 shares.</p>\n<p>Following the repurchase, the number of issued shares (excluding treasury shares) decreased to 106,528,185, while treasury shares increased to 2,568,600. The total number of issued shares remained at 109,096,785. Repurchase prices ranged between HKD 9.81 and HKD 10.74, resulting in an aggregate consideration of approximately HKD 7.26 million.</p>\n<p>According to the disclosure, there is a moratorium period extending to 6 March 2026, during which no new shares may be issued or released from treasury without prior approval. The update reflects the most recent changes in the company’s shareholding structure recorded as of 4 February 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1137991191","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137991191","pubTimestamp":1770204537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed a repurchase of 680,400 H shares on 4 February 2026. The company’s opening balance on 3 February 2026 showed 107,208,585 issued...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"杭州九元基因生物制药(02566)呈报股份购回及更新股权架构","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed a repurchase of 680,400 H shares on 4 February 2026. The company’s opening balance on 3 February 2026 showed 107,208,585 issued shares (excluding treasury shares) and 1,888,200 treasury shares, totaling 109,096,785 shares.\nFollowing the repurchase, the number of issued shares (excluding treasury shares) decreased to 106,528,185, while treasury shares increased to 2,568,600. The total number of issued shares remained at 109,096,785. Repurchase prices ranged between HKD 9.81 and HKD 10.74, resulting in an aggregate consideration of approximately HKD 7.26 million.\nAccording to the disclosure, there is a moratorium period extending to 6 March 2026, during which no new shares may be issued or released from treasury without prior approval. The update reflects the most recent changes in the company’s shareholding structure recorded as of 4 February 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}